江苏康缘药业股份有限公司关于实际控制人的一致行动人增持公司股份的公告

Core Viewpoint - Jiangsu Kangyuan Pharmaceutical Co., Ltd. announced that its actual controller's concerted actors have increased their shareholding in the company, reflecting confidence in the company's future development and long-term investment value [2][3]. Group 1: Shareholding Increase Details - The concerted actors, Mr. Xiao Lihao and Ms. Zhao Shiwen, purchased a total of 80,000 shares, accounting for 0.0141% of the company's total share capital, with a total investment amount of 1,252,109 yuan (excluding transaction fees) [2][3]. - This increase in shareholding does not trigger the obligation to report changes in equity [2][3]. Group 2: Legal Compliance and Future Plans - The increase in shareholding does not result in any changes to the company's controlling shareholder or actual controller [3][6]. - The company has received notification from the concerted actors that they currently have no further plans for additional share purchases, but will comply with legal disclosure obligations if future plans arise [3][4]. Group 3: Legal Opinions - Jiangsu Shiji Tongren Law Firm provided a special verification opinion, confirming that the shareholders involved in the increase have the qualifications to execute this action and that it complies with relevant laws and regulations [4][5]. - The increase in shareholding is exempt from the requirement to issue a tender offer [4][5].